To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01725126 on ClinicalTrials.gov · last registry update 2017-12-13

A small phase 2 — 53 participants, against a typical 110. The sponsor logged completion for 12 September 2013. Primary outcome, as filed: Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE) or Death During Part A. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Enrollment: 53
Started: 2013-02-10
Primary completion: 2013-09-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE) or Death During Part A

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.